Chrys Kokino

As President of Accord North America, Chrys Kokino brings over 35 years of experience in commercializing biosimilars, specialty products, and complex molecules across global markets, including the U.S., EU, Asia, and MENA. As an early pioneer in the regulated biosimilar market, he was on the ground floor when biosimilars first launched and has the distinction of launching some of the world's first biosimilars while at Sandoz and Mylan. In his current role, Chrys is focused on expanding access to biosimilars across high-need therapeutic areas – including oncology and immunology – where cost-effective treatment options remain limited despite significant patient populations impacted by chronic disease. With 7 FDA-approved therapies and a pipeline built for scale, Accord is driving toward an ambitious goal: 20 biosimilars to market by 2030 and a position as the leading biosimilar provider in the U.S.